Oil & Gas Integrated
Compare Stocks
5 / 10Stock Comparison
SU vs CNQ vs CVX vs CVE vs XOM
Revenue, margins, valuation, and 5-year total return — side by side.
Oil & Gas Exploration & Production
Oil & Gas Integrated
Oil & Gas Integrated
Oil & Gas Integrated
SU vs CNQ vs CVX vs CVE vs XOM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Oil & Gas Integrated | Oil & Gas Exploration & Production | Oil & Gas Integrated | Oil & Gas Integrated | Oil & Gas Integrated |
| Market Cap | $75.97B | $92.89B | $362.06B | $53.49B | $611.92B |
| Revenue (TTM) | $52.01B | $40.74B | $184.43B | $49.40B | $323.90B |
| Net Income (TTM) | $6.33B | $9.71B | $12.30B | $4.64B | $28.84B |
| Gross Margin | 55.5% | 30.8% | 30.4% | 19.6% | 21.7% |
| Operating Margin | 27.4% | 26.8% | 9.0% | 14.0% | 10.5% |
| Forward P/E | 7.5x | 7.7x | 14.7x | 6.6x | 14.3x |
| Total Debt | $18.37B | $19.71B | $46.74B | $17.00B | $43.54B |
| Cash & Equiv. | $3.65B | $672M | $6.47B | $2.74B | $10.68B |
SU vs CNQ vs CVX vs CVE vs XOM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Suncor Energy Inc. (SU) | 100 | 373.9 | +273.9% |
| Canadian Natural Re… (CNQ) | 100 | 492.0 | +392.0% |
| Chevron Corporation (CVX) | 100 | 197.9 | +97.9% |
| Cenovus Energy Inc. (CVE) | 100 | 655.9 | +555.9% |
| Exxon Mobil Corpora… (XOM) | 100 | 317.6 | +217.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SU vs CNQ vs CVX vs CVE vs XOM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SU is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta -0.11, Low D/E 40.7%, current ratio 1.39x
CNQ carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 23.9%, EPS growth 81.1%, 3Y rev CAGR -3.7%
- 301.0% 10Y total return vs SU's 198.4%
- 23.9% revenue growth vs CVE's -14.0%
- 23.8% margin vs CVX's 6.7%
CVX is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 8 yrs, beta -0.11, yield 3.8%
- Beta -0.11, yield 3.8%, current ratio 1.15x
CVE is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (6.6x vs 14.3x)
- +127.1% vs CVX's +37.4%
XOM ranks third and is worth considering specifically for stability.
- Lower D/E ratio (16.3% vs 53.8%)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.9% revenue growth vs CVE's -14.0% | |
| Value | Lower P/E (6.6x vs 14.3x) | |
| Quality / Margins | 23.8% margin vs CVX's 6.7% | |
| Stability / Safety | Lower D/E ratio (16.3% vs 53.8%) | |
| Dividends | 3.8% yield, 2-year raise streak, vs XOM's 2.8% | |
| Momentum (1Y) | +127.1% vs CVX's +37.4% | |
| Efficiency (ROA) | 10.9% ROA vs CVX's 4.2%, ROIC 10.0% vs 6.2% |
SU vs CNQ vs CVX vs CVE vs XOM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SU vs CNQ vs CVX vs CVE vs XOM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SU leads in 1 of 6 categories
CNQ leads 1 • CVE leads 1 • CVX leads 0 • XOM leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
SU leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
XOM is the larger business by revenue, generating $323.9B annually — 8.0x CNQ's $40.7B. CNQ is the more profitable business, keeping 23.8% of every revenue dollar as net income compared to CVX's 6.7%. On growth, SU holds the edge at +25.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $52.0B | $40.7B | $184.4B | $49.4B | $323.9B |
| EBITDAEarnings before interest/tax | $21.7B | $20.5B | $37.1B | $12.4B | $59.9B |
| Net IncomeAfter-tax profit | $6.3B | $9.7B | $12.3B | $4.6B | $28.8B |
| Free Cash FlowCash after capex | $7.2B | $5.3B | $16.2B | $4.4B | $23.6B |
| Gross MarginGross profit ÷ Revenue | +55.5% | +30.8% | +30.4% | +19.6% | +21.7% |
| Operating MarginEBIT ÷ Revenue | +27.4% | +26.8% | +9.0% | +14.0% | +10.5% |
| Net MarginNet income ÷ Revenue | +12.2% | +23.8% | +6.7% | +9.4% | +8.9% |
| FCF MarginFCF ÷ Revenue | +13.9% | +13.1% | +8.8% | +8.8% | +7.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.1% | -14.7% | -5.3% | -12.8% | -1.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +30.1% | -45.3% | -24.5% | +78.7% | -11.0% |
Valuation Metrics
Evenly matched — SU and CVE each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 11.8x trailing earnings, CNQ trades at a 57% valuation discount to CVX's 27.4x P/E. On an enterprise value basis, SU's 5.2x EV/EBITDA is more attractive than CVX's 10.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $76.0B | $92.9B | $362.1B | $53.5B | $611.9B |
| Enterprise ValueMkt cap + debt − cash | $86.7B | $106.8B | $402.3B | $63.9B | $644.8B |
| Trailing P/EPrice ÷ TTM EPS | 18.03x | 11.79x | 27.37x | 18.05x | 21.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.50x | 7.66x | 14.68x | 6.55x | 14.31x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 5.16x | 9.22x | 10.84x | 8.90x | 10.76x |
| Price / SalesMarket cap ÷ Revenue | 2.12x | 2.87x | 1.96x | 1.47x | 1.89x |
| Price / BookPrice ÷ Book value/share | 2.37x | 2.88x | 1.75x | 2.23x | 2.33x |
| Price / FCFMarket cap ÷ FCF | 15.00x | 15.07x | 21.82x | 21.46x | 25.92x |
Profitability & Efficiency
CNQ leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
CNQ delivers a 22.7% return on equity — every $100 of shareholder capital generates $23 in annual profit, vs $7 for CVX. XOM carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVE's 0.54x. On the Piotroski fundamental quality scale (0–9), CNQ scores 8/9 vs XOM's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +14.0% | +22.7% | +7.2% | +15.2% | +10.7% |
| ROA (TTM)Return on assets | +7.0% | +10.9% | +4.2% | +7.8% | +6.4% |
| ROICReturn on invested capital | +20.1% | +10.0% | +6.2% | +7.9% | +8.6% |
| ROCEReturn on capital employed | +19.5% | +10.3% | +6.6% | +8.2% | +8.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 5 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.41x | 0.44x | 0.24x | 0.54x | 0.16x |
| Net DebtTotal debt minus cash | $14.7B | $19.0B | $40.3B | $14.3B | $32.9B |
| Cash & Equiv.Liquid assets | $3.6B | $672M | $6.5B | $2.7B | $10.7B |
| Total DebtShort + long-term debt | $18.4B | $19.7B | $46.7B | $17.0B | $43.5B |
| Interest CoverageEBIT ÷ Interest expense | 11.68x | 23.26x | 17.22x | 11.80x | 69.44x |
Total Returns (Dividends Reinvested)
CVE leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVE five years ago would be worth $39,812 today (with dividends reinvested), compared to $19,379 for CVX. Over the past 12 months, CVE leads with a +127.1% total return vs CVX's +37.4%. The 3-year compound annual growth rate (CAGR) favors SU at 31.9% vs CVX's 8.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +41.4% | +31.1% | +17.5% | +62.8% | +18.6% |
| 1-Year ReturnPast 12 months | +91.9% | +54.0% | +37.4% | +127.1% | +39.9% |
| 3-Year ReturnCumulative with dividends | +129.6% | +72.4% | +26.0% | +84.9% | +43.0% |
| 5-Year ReturnCumulative with dividends | +205.8% | +202.7% | +93.8% | +298.1% | +160.6% |
| 10-Year ReturnCumulative with dividends | +198.4% | +301.0% | +134.7% | +117.8% | +102.6% |
| CAGR (3Y)Annualised 3-year return | +31.9% | +19.9% | +8.0% | +22.7% | +12.7% |
Risk & Volatility
Evenly matched — CVE and XOM each lead in 1 of 2 comparable metrics.
Risk & Volatility
XOM is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than CVE's 0.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVE currently trades 92.1% from its 52-week high vs XOM's 81.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.11x | -0.09x | -0.11x | 0.15x | -0.20x |
| 52-Week HighHighest price in past year | $70.29 | $51.34 | $214.71 | $30.84 | $176.41 |
| 52-Week LowLowest price in past year | $34.04 | $29.27 | $133.77 | $11.96 | $101.19 |
| % of 52W HighCurrent price vs 52-week peak | +91.1% | +86.7% | +84.5% | +92.1% | +81.8% |
| RSI (14)Momentum oscillator 0–100 | 47.1 | 44.2 | 39.2 | 58.9 | 39.5 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 11.3M | 11.0M | 12.9M | 18.9M |
Analyst Outlook
Evenly matched — CNQ and XOM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SU as "Buy", CNQ as "Buy", CVX as "Buy", CVE as "Hold", XOM as "Hold". Consensus price targets imply 11.6% upside for XOM (target: $161) vs -21.4% for CNQ (target: $35). For income investors, CNQ offers the higher dividend yield at 3.81% vs CVE's 2.01%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $62.00 | $35.00 | $194.87 | $27.67 | $161.08 |
| # AnalystsCovering analysts | 31 | 37 | 53 | 27 | 55 |
| Dividend YieldAnnual dividend ÷ price | +2.6% | +3.8% | +3.8% | +2.0% | +2.8% |
| Dividend StreakConsecutive years of raises | 4 | 2 | 8 | 0 | 26 |
| Dividend / ShareAnnual DPS | $2.30 | $2.32 | $6.87 | $0.78 | $4.00 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.0% | +1.1% | +3.3% | +3.4% | +3.3% |
SU leads in 1 of 6 categories (Income & Cash Flow). CNQ leads in 1 (Profitability & Efficiency). 3 tied.
SU vs CNQ vs CVX vs CVE vs XOM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SU or CNQ or CVX or CVE or XOM a better buy right now?
For growth investors, Canadian Natural Resources Limited (CNQ) is the stronger pick with 23.
9% revenue growth year-over-year, versus -14. 0% for Cenovus Energy Inc. (CVE). Canadian Natural Resources Limited (CNQ) offers the better valuation at 11. 8x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate Suncor Energy Inc. (SU) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SU or CNQ or CVX or CVE or XOM?
On trailing P/E, Canadian Natural Resources Limited (CNQ) is the cheapest at 11.
8x versus Chevron Corporation at 27. 4x. On forward P/E, Cenovus Energy Inc. is actually cheaper at 6. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SU or CNQ or CVX or CVE or XOM?
Over the past 5 years, Cenovus Energy Inc.
(CVE) delivered a total return of +298. 1%, compared to +93. 8% for Chevron Corporation (CVX). Over 10 years, the gap is even starker: CNQ returned +301. 0% versus XOM's +102. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SU or CNQ or CVX or CVE or XOM?
By beta (market sensitivity over 5 years), Exxon Mobil Corporation (XOM) is the lower-risk stock at -0.
20β versus Cenovus Energy Inc. 's 0. 15β — meaning CVE is approximately -175% more volatile than XOM relative to the S&P 500. On balance sheet safety, Exxon Mobil Corporation (XOM) carries a lower debt/equity ratio of 16% versus 54% for Cenovus Energy Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SU or CNQ or CVX or CVE or XOM?
By revenue growth (latest reported year), Canadian Natural Resources Limited (CNQ) is pulling ahead at 23.
9% versus -14. 0% for Cenovus Energy Inc. (CVE). On earnings-per-share growth, the picture is similar: Canadian Natural Resources Limited grew EPS 81. 1% year-over-year, compared to -31. 8% for Chevron Corporation. Over a 3-year CAGR, CNQ leads at -3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SU or CNQ or CVX or CVE or XOM?
Canadian Natural Resources Limited (CNQ) is the more profitable company, earning 24.
5% net margin versus 6. 7% for Chevron Corporation — meaning it keeps 24. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SU leads at 31. 7% versus 8. 8% for CVE. At the gross margin level — before operating expenses — SU leads at 59. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SU or CNQ or CVX or CVE or XOM more undervalued right now?
On forward earnings alone, Cenovus Energy Inc.
(CVE) trades at 6. 6x forward P/E versus 14. 7x for Chevron Corporation — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XOM: 11. 6% to $161. 08.
08Which pays a better dividend — SU or CNQ or CVX or CVE or XOM?
All stocks in this comparison pay dividends.
Canadian Natural Resources Limited (CNQ) offers the highest yield at 3. 8%, versus 2. 0% for Cenovus Energy Inc. (CVE).
09Is SU or CNQ or CVX or CVE or XOM better for a retirement portfolio?
For long-horizon retirement investors, Canadian Natural Resources Limited (CNQ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
09), 3. 8% yield, +301. 0% 10Y return). Both have compounded well over 10 years (CNQ: +301. 0%, CVE: +117. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SU and CNQ and CVX and CVE and XOM?
Both stocks operate in the Energy sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SU is a mid-cap quality compounder stock; CNQ is a mid-cap high-growth stock; CVX is a large-cap income-oriented stock; CVE is a mid-cap quality compounder stock; XOM is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.